For example, one study showed a correlation between RhoA GTPase overexpression and cell motility in breast cancer [6], and another demonstrated that the coexpression rate of delta-catenin, which regulates the cytoskeleton and RhoA expression, was stronger in stage III–IV lung cancer than in stage I–II lung cancer [7]. This evidence concerns the gene CTNND2 and lung cancer.